News Releases

March 6, 2019
Urovant Sciences Appoints James Robinson to its Board of Directors
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson , President and Chief Operating
Additional Formats
February 6, 2019
Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter
Additional Formats
Displaying 1 - 10 of 11